Phase II copanlisib in relapsed or refractory DLBCL

• Research type

  Research Study

• Full title

  An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and the impact of biomarkers thereupon.

• IRAS ID

  174724

• Contact name

  William Liu

• Contact email

  william.liu@bayer.com

• Sponsor organisation

  Bayer HealthCare AG

• Eudract number

  2014-004848-36

• Clinicaltrials.gov Identifier

  NCT02391116

• Duration of Study in the UK

  3 years, 0 months, 7 days

• Research summary

  To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-Cell lymphoma (DLBCL) and assess the relationship between efficacy and a potentially predictive biomarker.

• REC name

  London - Central Research Ethics Committee

• REC reference

  15/LO/1006

• Date of REC Opinion

  10 Jul 2015

• REC opinion

  Further Information Favourable Opinion